Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $2.6 million.

  • Lyell Immunopharma's Depreciation & Amortization (CF) fell 4517.09% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.2 million, marking a year-over-year decrease of 2794.22%. This contributed to the annual value of $19.6 million for FY2024, which is 305.68% down from last year.
  • Latest data reveals that Lyell Immunopharma reported Depreciation & Amortization (CF) of $2.6 million as of Q3 2025, which was down 4517.09% from $3.1 million recorded in Q2 2025.
  • Lyell Immunopharma's 5-year Depreciation & Amortization (CF) high stood at $5.1 million for Q3 2023, and its period low was $2.0 million during Q1 2021.
  • For the 5-year period, Lyell Immunopharma's Depreciation & Amortization (CF) averaged around $4.2 million, with its median value being $4.6 million (2022).
  • In the last 5 years, Lyell Immunopharma's Depreciation & Amortization (CF) soared by 27056.16% in 2021 and then plummeted by 4517.09% in 2025.
  • Lyell Immunopharma's Depreciation & Amortization (CF) (Quarter) stood at $4.6 million in 2021, then increased by 10.43% to $5.0 million in 2022, then increased by 0.32% to $5.1 million in 2023, then decreased by 0.61% to $5.0 million in 2024, then tumbled by 48.95% to $2.6 million in 2025.
  • Its Depreciation & Amortization (CF) was $2.6 million in Q3 2025, compared to $3.1 million in Q2 2025 and $3.4 million in Q1 2025.